L04AX06 · Antineoplastic and immunomodulating agents
Pomalidomide Zentiva
Indications
Treatment of adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Pomalidomide Zentiva in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Composition
- Active substance
- Pomalidomide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Pomalidomide Zentiva
- Active substance
- Pomalidomide
- ATC code
- L04AX06
- Therapeutic area